IPSEN, OOO
- Country
- 🇷🇺Russia
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 18
- Registration Number
- NCT06730061
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
- Conditions
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 641
- Registration Number
- NCT06625060
- Locations
- 🇺🇸
MD First Research - Chandler, Chandler, Arizona, United States
🇺🇸Profound Research. LLC - NCSC, Carlsbad, California, United States
🇺🇸WR-PRI Encino, Encino, California, United States
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
- Conditions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 424
- Registration Number
- NCT06447168
- Locations
- 🇺🇸
Velocity Clinical Research, Katy, Texas, United States
🇺🇸Gastro health & Nutrition, Seattle, Washington, United States
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 72
- Registration Number
- NCT06383403
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸Methodist Transplant Physicians, Dallas, Texas, United States
🇺🇸Velocity Liver Institute NW, Seattle, Washington, United States
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 90
- Registration Number
- NCT06341712
- Locations
- 🇧🇪
Universitaire Ziekenhuizen Leuven, Leuven, Belgium
🇨🇦Princess Margaret cancer center, Toronto, Canada
🇺🇸University of Southern California (USC) - Norris Cancer Hospital, Los Angeles, California, United States
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 220
- Registration Number
- NCT06305247
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute - California, Los Angeles, California, United States
🇺🇸UC San Diego Health System - La Jolla, San Diego, California, United States
🇺🇸Yale Cancer Center - New Heaven, New Haven, Connecticut, United States
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
- Conditions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 20
- Registration Number
- NCT06258902
- Locations
- 🇺🇸
Virtual Research Coordination Center Odevixibat (BYLVAY) Pregnancy Surveillance Program, Wilmington, North Carolina, United States
A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
- Conditions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 20
- Registration Number
- NCT06253897
- Locations
- 🇺🇸
Pearl IRB, Indianapolis, Indiana, United States
CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity
- Conditions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 133
- Registration Number
- NCT06245772
- Locations
- 🇫🇷
Crf Bel Air, La Membrolle-sur-Choisille, France
🇫🇷Le Centre Médical Germaine Revel, Saint-Maurice-sur-Dargoire, France
🇫🇷CH Bagnères, Bagnères-de-Bigorre, France
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
- Conditions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 70
- Registration Number
- NCT06089616